Board of Directors

David W Anderson – Chairman

Mr Anderson has been a successful entrepreneur in the orthopaedic medical device field for over 20 years. He has led four orthopaedic organizations; Osteotech (Executive VP), Bionx Implants (CEO), Replication Medical (Founder and Director), and Gentis (CEO). Mr. Anderson was a founder of Osteotech and was the founder and CEO of Bionx Implants which he grew through over 60 product approvals to over $20 million in sales in less than three years. He was also part of the team that created Integra LifeSciences and was an active member of the Board of Directors of Replication Medical. He has raised over $150 million in venture capital, taken a company through the IPO route onto NASDAQ, and has been a part of multiple M&A transactions.

Dianne Blanco – Chief Executive Officer

Mrs Blanco spent 14 years at Baxter Healthcare growing medical device/pharmaceutical divisions in the US, Europe and globally. She started at Baxter leading a new initiative to build a division to develop market products for healthcare outside the hospital a non-traditional market for Baxter. In three years, she built the division to over $200 million in sales. In her latest position she spent over five years as President of the European division with P&L responsibility for more than 500 employees and over three-quarters of a billion dollars in sales. The organization grew almost 20 percent annually in the last three years. She was responsible for bringing many new products to market during her tenure, including a critical care therapy that revitalized a large division and moved it from a distant number three in the market to market leader.

Shaun Claydon ACA – Chief Financial Officer

Mr. Claydon has over 16 years experience as a corporate financier, latterly within the UK investment banking industry. During his career he has advised a wide range of companies on fundraising, M&A and private equity transactions both in the UK and International public and private markets. Mr. Claydon has advised numerous UK Life Science companies on IPOs, secondary offerings and other corporate transactions. A qualified chartered accountant, he has held senior positions within corporate finance at PwC, Evolution Securites and HSBC Investment Banking.

Richard Lyman – Non Executive Director

Mr Lyman is a Managing Director of Oakes, Lyman & Co. Limited. Additionally, in his corporate career he was President of Squibb’s Medical Systems International Group. In his career in venture capital he formed a number of start-up companies including Biotechnology General Inc. (where he was Chairman and CEO), Life Technologies – now Invitrogen Corporation (Chairman and CEO), Medimmune Inc (Director), Genetic Therapy Inc. (Chairman), Osteotech Inc. (Chairman) and Quadrant Healthcare plc (Chairman and CEO).

Joseph W Kaufmann – Observer

Mr Kaufmann is President and CEO of Kensey Nash Corporation, a medical device company focused on regenerative medicine. Mr. Kaufmann joined Kensey Nash in 1989 as Chief Financial Officer and was appointed Vice President, Finance and Administration in January 1994. Prior to joining the company, he held executive finance positions at divisions of both Hanson PLC and Syntex Corporation. Mr. Kaufmann received a B.S. degree in Accounting from St. Joseph’s University.